Search / 52493 results found

from
to
  • Updated

As they reel from revenue losses connected to the pandemic, many colleges and universities are racking up other costs not likely to turn up in their glossy brochures or as line items on staggering tuition bills: untold millions of dollars in legal fees and settlements for allegedly violating the rights of students, professors, and applicants on free speech, admissions and other matters as the schools pursue social justice causes.

NEW BRUNSWICK, N.J., Oct. 15, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine.

Early voting for November’s city elections began this week, and while only a handful of Georgia’s municipalities are holding contested mayoral elections, Atlanta’s will undoubtedly have the most impact throughout the state. “Lots of groups rate Georgia very highly as a business-friendly state, and Atlanta as a forward-looking city,” said Tom Smith, an economics professor […]

  • Updated

CARMIEL, Israel and BOSTON, Oct. 15, 2021 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced the final dosing of the last patient in the phase III BALANCE clinical trial of pegunigalsidase alfa (PRX–102), or the BALANCE Study, for the proposed treatment of Fabry disease. The head-to-head BALANCE Study is designed to evaluate the safety and efficacy of PRX–102 compared to agalsidase beta (Fabrazyme®) on renal function in Fabry patients with progressing kidney disease previously treated with agalsidase beta.